Personalized cancer vax shows promise against glioblastomas in study

A personalized cancer vaccine has shown promise against glioblastomas, the most common malignant brain tumor. In a Phase I trial, 91 percent of patients receiving the vaccine--which was created using the patient's dendritic cells--survived one year, while 55 percent lived two years and 44 percent of patients were alive for three or more years after vaccination. The majority of glioblastoma patients die within 12 to 14 months of diagnosis. The vaccine has already entered Phase II trials, and a Phase III trial is enrolling patients. Story